This company has been marked as potentially delisted and may not be actively trading. Soaring Eagle Acquisition (SRNG) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock SRNG vs. PRME, JATT, PLX, IKT, IZTC, CRTX, ZIVO, ALVR, CVM, and FNCHShould you be buying Soaring Eagle Acquisition stock or one of its competitors? The main competitors of Soaring Eagle Acquisition include Prime Medicine (PRME), JATT Acquisition (JATT), Protalix BioTherapeutics (PLX), Inhibikase Therapeutics (IKT), Invizyne Technologies (IZTC), Cortexyme (CRTX), ZIVO Bioscience (ZIVO), AlloVir (ALVR), CEL-SCI (CVM), and Finch Therapeutics Group (FNCH). Soaring Eagle Acquisition vs. Its Competitors Prime Medicine JATT Acquisition Protalix BioTherapeutics Inhibikase Therapeutics Invizyne Technologies Cortexyme ZIVO Bioscience AlloVir CEL-SCI Finch Therapeutics Group Soaring Eagle Acquisition (NASDAQ:SRNG) and Prime Medicine (NYSE:PRME) are both biological products, except diagnostic industry companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation. Do insiders & institutionals have more ownership in SRNG or PRME? 41.2% of Soaring Eagle Acquisition shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 22.7% of Prime Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend SRNG or PRME? Prime Medicine has a consensus price target of $8.92, suggesting a potential upside of 154.76%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Prime Medicine is more favorable than Soaring Eagle Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soaring Eagle Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Prime Medicine 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75 Does the media refer more to SRNG or PRME? In the previous week, Prime Medicine had 9 more articles in the media than Soaring Eagle Acquisition. MarketBeat recorded 9 mentions for Prime Medicine and 0 mentions for Soaring Eagle Acquisition. Prime Medicine's average media sentiment score of 0.29 beat Soaring Eagle Acquisition's score of 0.20 indicating that Prime Medicine is being referred to more favorably in the news media. Company Overall Sentiment Soaring Eagle Acquisition Neutral Prime Medicine Neutral Is SRNG or PRME more profitable? Soaring Eagle Acquisition's return on equity of 0.00% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Soaring Eagle AcquisitionN/A N/A N/A Prime Medicine N/A -107.87%-74.97% Which has preferable valuation & earnings, SRNG or PRME? Soaring Eagle Acquisition has higher earnings, but lower revenue than Prime Medicine. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSoaring Eagle AcquisitionN/AN/AN/AN/AN/APrime Medicine$4.96M94.94-$198.13M-$1.56-2.24 SummaryPrime Medicine beats Soaring Eagle Acquisition on 9 of the 11 factors compared between the two stocks. Get Soaring Eagle Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for SRNG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SRNG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRNG vs. The Competition Export to ExcelMetricSoaring Eagle AcquisitionBiological Products, Except Diagnostic IndustryEnergy SectorNASDAQ ExchangeMarket Cap$2.84B$282.09M$7.71B$9.79BDividend YieldN/AN/A10.98%4.10%P/E RatioN/AN/A72.6325.29Price / SalesN/A577.8625,665.9888.61Price / CashN/A22.4435.1728.45Price / BookN/A9.823.976.00Net IncomeN/A-$115.81M$4.26B$265.34M Soaring Eagle Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRNGSoaring Eagle AcquisitionN/A$13.18+2.2%N/A+5,850.3%$2.84BN/A0.00N/APRMEPrime Medicine3.5681 of 5 stars$3.79+3.0%$8.92+135.3%-15.8%$509.74M$3.85M-1.85234JATTJATT AcquisitionN/A$1.42-4.1%N/A-49.4%$140.76MN/A0.003High Trading VolumePLXProtalix BioTherapeutics3.2227 of 5 stars$1.54+2.0%$15.00+874.0%+52.4%$122.60M$59.76M-11.85200IKTInhibikase Therapeutics2.0326 of 5 stars$1.43-7.7%$6.50+354.5%+37.8%$106.31MN/A-0.546IZTCInvizyne TechnologiesN/A$9.84-1.7%N/AN/A$61.52MN/A0.0029Gap DownCRTXCortexymeN/A$1.65-1.2%N/A+208.0%$58.79MN/A-0.5655ZIVOZIVO Bioscience0.2477 of 5 stars$14.49flatN/A+115.5%$55.31M$15.85K-2.9710ALVRAlloVirN/A$2.67-1.5%N/A-85.6%$49.48MN/A-0.13110CVMCEL-SCI1.2638 of 5 stars$7.44-9.6%N/A-74.3%$39.59MN/A-15.5043Short Interest ↓FNCHFinch Therapeutics GroupN/A$12.45flatN/A-1.9%$19.99MN/A-1.41190 Related Companies and Tools Related Companies PRME Alternatives JATT Alternatives PLX Alternatives IKT Alternatives IZTC Alternatives CRTX Alternatives ZIVO Alternatives ALVR Alternatives CVM Alternatives FNCH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRNG) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soaring Eagle Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soaring Eagle Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access